Novo Nordisk and Evotec LAB eN2 – Johns Hopkins University Collaboration
Internal — Johns Hopkins University only
The Novo Nordisk and Evotec LAB eN2 – Johns Hopkins University Collaboration supports Johns Hopkins researchers developing targets, disease insights, and tools to advance cardio-metabolic and rare blood disease discoveries.
Funder: Johns Hopkins University
Due Dates: Rolling (Project Concept Forms)
Funding Amounts: Up to $4,000,000 per award
Summary: This collaboration advances Johns Hopkins discoveries toward investigational new drug (IND)-ready candidates for cardio-metabolic diseases and rare blood disorders.
Key Information: Only Johns Hopkins faculty at the assistant, associate, or full professor level may submit a pre-proposal.
Description
LAB eN2 is a research collaboration among Johns Hopkins University, Novo Nordisk, and Evotec. It aims to accelerate academic discoveries toward investigational new drug (IND)-ready candidates for cardio-metabolic diseases and rare blood disorders. The collaboration funds Johns Hopkins research that identifies new targets, generates insights into disease biology, or develops novel research tools.
Areas of interest include diabetes, obesity, chronic diseases, and rare diseases. The collaboration also considers technology platforms and approaches that are not tied to a particular modality, connecting disease-focused discoveries and broader research tools with a path toward IND-ready candidates.
